BroadOak Fund

BroadOak Capital Partners, LLC is a privately held investment bank dedicated to the life sciences sector. The firm provides a range of advisory services, including mergers and acquisitions, divestitures, business combinations, capital formation, valuations, and fairness opinions. BroadOak's expertise spans various areas within the life sciences, such as research tools and consumables, diagnostics, therapeutics, healthcare IT, pharmaceutical services, and medical devices. Additionally, the firm has an investment arm that specializes in private equity and venture capital, focusing on growth capital investments in life sciences tools and services. Based in Bethesda, Maryland, BroadOak Capital Partners plays a significant role in supporting the development and expansion of innovative companies in the life sciences industry.

Aaron Fisher

vice_president

Lars Hanan

Partner

Bryan Poltilove

MD

Kyle Wilson

Partner

36 past transactions

Kromatid

Venture Round in 2021
KromaTiD focuses on advancing the knowledge of genetic abnormalities and diseases by developing molecular cytogenetics assays and reagents. It's molecular cytogenetic and GeneTracker assays discover, detect, and diagnose the range of disease-causing mutations - including inversions and translocations - in a single test. Based on Directional Genomic Hybridization (dGH), KromaTiD's assays generate the sequence, location, and orientation data from single cells, making them ideal for mixed cell population studies Co-founders Andrew Ray, Joel Bedford, Michael Cornforth, and Susan M. Bailey headquartered the company in Fort Collins, Colorado in 2007.

Former Assets and All Related Asset Rights of MedCision, Inc

Merger/Acquisition in 2018
As of May 23, 2018, Former Assets and All Related Asset Rights of MedCision, Inc was acquired by Astero Bio Corporation. Former Assets and All Related Asset Rights of MedCision, Inc comprises an automated instrument created to de-risk thawing of live cell therapeutics and other assets.

BioCision, LLC

Venture Round in 2012
BioCision’s mission is to standardize pre-analytical sample handling. They develop novel products that eliminate variability in common, often-overlooked, laboratory procedures. Their products are marketed globally and are widely used by the leading institutions in the biotech, pharmaceutical, clinical, diagnostic, academic and government scientific community. BioCision’s products include CoolRack®, CoolSink™ and ThermalTray™ laboratory tube and plate temperature standardizing modules, CoolBox™ ice-free benchtop coolers, CoolCell® alcohol-free cell freezing containers and TruCool™ accessories and consumables.

PBS Biotech

Venture Round in 2021
PBS Biotech, Inc, produces the easiest to use and most technologically-advanced bioreactors for the pharmaceutical industry. Their single-use bioreactors have the smallest per liter volume footprints and are fully scalable for any stage of the cell culture process, from R&D to clinical to cGMP production. They provide efficient, cost-effective disposable systems and top-notch technical services to help their customers solve complex cell culture challenges.

Bioinformatics

Series B in 2018
Bioinformatics, Inc. is a market research firm supporting the analytical instrumentation and life science industries.Their expertise includes assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customers’ brand loyalty, and evaluating brand strength and positioning. Their multi-disciplinary team is comprised of industry veterans, market research experts, consultants and survey statisticians.

Halo Labs Inc. (OTCPK:AGEE.F)

Private Placement in 2018
Halo Labs Inc. operates as a cannabis cultivation, manufacturing, and distribution company that grows, extracts, and processes cannabis flower, oils, and concentrates. The company also offers edible products in California and Oregon. It serves licensed retailers and wholesalers. Halo Labs Inc. has a strategic partnership with High Tide Inc; and with OG DNA Genetics Inc to develop genetics in Oregon. The company was founded in 2016 and is headquartered in Toronto, Canada.

LabConnect

Series A in 2017
LabConnect provides global central laboratory services, including routine and esoteric laboratory testing, kit building, sample management, biorepository and scientific support services for biopharmaceutical, medical device and contract research organizations. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets and extensive specialized testing expertise means that drug development companies can rely on one provider for all your central laboratory service needs.

Rubicon Genomics

Venture Round in 2015
Rubicon Genomics was founded in 2000 by two University of Michigan faculty members, Dr. John Langmore and Dr. Vladimir Makarov, who wanted to advance the translation of human genetics “laboratory knowledge” into practical medicine applications. The founders also decided to maintain the company’s roots in Michigan with a commitment to supporting the Michigan economy. Today, Rubicon Genomics is a privately held company located in Ann Arbor, Michigan and employs 20 administrative and technical staff. Our innovative products combined with our strategic partnerships have established the company as a leader in pre-analytical amplification technologies that "break the sample barriers" for our customers. Rubicon sells its products into the research and commercial markets directly and through distributors

Pluristyx

Venture Round in 2023
Pluristyx provides the expertise and tools to support and accelerate the development and commercialization of revolutionary therapeutics to treat serious human diseases by providing unique products, expert consulting, and contract services.

S2 Genomics

Series A in 2024
S2 Genomics, Inc. develops integrated sample preparation systems that processes tissues and liquid samples into genomic samples. The company also provides spatial sequencing technology that captures three dimensional coordinates of single cells in tissue for NGS readout. S2 Genomics, Inc. was founded in 2016 and is based in Livermore, California.

Sanguine

Venture Round in 2023
Sanguine develops innovative technology solutions for clinical researchers. The company facilitates clinical trials by recruiting participants, conducting at-home data collection, and processing samples, enabling clinicians to prescribe the right medicines.

Genomenon

Series A in 2021
Genomenon, Inc. develops a suite of software tools to prioritize data points for decision-making in genetic diagnoses and discoveries. The company offers GENOMENON, a software solution that allows rapid, automated, and accurate analysis of next-generation sequencing data to speed up discovery work and diagnosis. Its diagnostic and discovery tools enable physicians and researchers to identify disease-causing variants from genomic-sequencing datasets. The company was incorporated in 2014 and is based in Ann Arbor, Michigan.

seqWell

Series C in 2022
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory services. It features a technology platform that serves as a transformative library prep technology that allows for simple, scalable multiplexing of 100s to 1000s of samples without time- and cost-consuming normalization. The company was founded in 2014 and headquartered in Massachusetts, United States.

Gemini Bio-Products

Private Equity Round in 2021
Gemini Bio-Products manufactures biological products and chemical reagents for the cell culture community globally. It offers cell culture sera, such as fetal bovine, specialized fetal bovine, other non-fetal, human and animal sera; custom and specialized media; and supplements and reagents, including amino acids, antibiotics and antimycotics, culture supplements and albumins, recombinant proteins, attachment factors, and cell dissociation reagents.

Accellix

Series E in 2021
Accelix is a biotechnology company that helps cell and gene therapy companies to meet their key product QC requirements. It provides an instrument and a room temperature stable cartridge to gather multi-parameter results. The company was founded in 2007 and headquartered in Yerushalayim, Israel.

Halo Labs

Series C in 2022
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

MedCision

Acquisition in 2018
MedCision is the world leader in next-generation automated cell thawing for advanced therapies. The company develops and commercializes technologies that automate and standardize vital preclinical and clinical biologics handling for critical post-manufacturing processes. MedCision’s digitally enabled ThawSTAR® Automated Cell Thawing Systems are designed to replace uncontrolled and highly variable manual methods, de-risking the therapeutic cell thawing process and optimizing cell efficacy. An industry first, ThawSTAR systems optimize cell thawing using a customizable algorithm for each unique cell therapy product and protocol. These systems, combined with MedCision’s ultra-low temperature cold storage and transport solutions, advance near-patient drug management by providing controlled and scalable processing of temperature-sensitive biotherapeutic products.

Genomenon

Series B in 2022
Genomenon, Inc. develops a suite of software tools to prioritize data points for decision-making in genetic diagnoses and discoveries. The company offers GENOMENON, a software solution that allows rapid, automated, and accurate analysis of next-generation sequencing data to speed up discovery work and diagnosis. Its diagnostic and discovery tools enable physicians and researchers to identify disease-causing variants from genomic-sequencing datasets. The company was incorporated in 2014 and is based in Ann Arbor, Michigan.

PhenoVista Biosciences

Venture Round in 2022
PhenoVista Biosciences is a niche contract research organization (CRO) providing high content imaging-based phenotypic assay development and screening services. Using state-of-the-art technology, PhenoVista Biosciences performs phenotypic screen feasibility, development, and full-scale campaigns. PhenoVista Biosciences' team of cell biologists work closely with clients to get the data they need on time and on budget.

Codex DNA

Series A in 2019
SGI-DNA provides a variety of synthetic genomic solutions to advance your research. Our comprehensive suite of genomic services will allow you to discover, design, and build the sequences you need. We are committed to reducing barriers associated with DNA synthesis and sequence analysis by leveraging the technology developed at the J. Craig Venter Institute and Synthetic Genomics, Inc. SGI-DNA, a wholly owned subsidiary of Synthetic Genomics, Inc (SGI), was founded in 2013 and is headquartered in La Jolla, CA. Building on the scientific advancements and breakthroughs from leading scientists such as J. Craig Venter, Ham Smith, Clyde Hutchison, Dan Gibson and their teams, SGI-DNA utilizes unique and proprietary DNA technologies to produce complex synthetic genes and reagents. SGI-DNA also offers a comprehensive suite of genomic services, including whole genome sequencing, library design, and other bioinformatics services. SGI-DNA is responsible for all commercial aspects of SGI’s synthetic DNA business and focuses on strategic business relationships with both academic and commercial researchers.

seqWell

Private Placement in 2019
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory services. It features a technology platform that serves as a transformative library prep technology that allows for simple, scalable multiplexing of 100s to 1000s of samples without time- and cost-consuming normalization. The company was founded in 2014 and headquartered in Massachusetts, United States.

InFuse Holdings

Private Placement in 2019
InFuse Holdings operates high-quality, cost-effective ambulatory infusion centers. The infrastructure in the US for infusion therapies is lacking and, in most communities today, infusions centers have a wide range of cost and quality. InFuse Holdings brings best practices – in the workflow, inventory management, scheduling, safety protocols, staffing, customer experience, and outcomes data collection and reporting – to provide patients with a convenient, safe, and caring environment. The ambulatory infusion center model allows InFuse to provide these services at a lower cost than other delivery channels, helping to decrease the overall cost of healthcare for patients, employers, and payors.

InFuse Holdings

Series A in 2019
InFuse Holdings operates high-quality, cost-effective ambulatory infusion centers. The infrastructure in the US for infusion therapies is lacking and, in most communities today, infusions centers have a wide range of cost and quality. InFuse Holdings brings best practices – in the workflow, inventory management, scheduling, safety protocols, staffing, customer experience, and outcomes data collection and reporting – to provide patients with a convenient, safe, and caring environment. The ambulatory infusion center model allows InFuse to provide these services at a lower cost than other delivery channels, helping to decrease the overall cost of healthcare for patients, employers, and payors.

Halo Labs

Private Placement in 2020
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Empire Genomics

Series B in 2016
Empire leverages genomics technologies, its keen understanding of the medical system, the needs of clinicians to deliver precise and continuous testing expertise for the best in class oncology disease management tools. Empire is a leader in the field of molecular diagnostics services.

Halo Labs

Series B in 2020
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Halo Labs

Series B in 2018
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

seqWell

Series B in 2020
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory services. It features a technology platform that serves as a transformative library prep technology that allows for simple, scalable multiplexing of 100s to 1000s of samples without time- and cost-consuming normalization. The company was founded in 2014 and headquartered in Massachusetts, United States.

Bioinformatics

Private Placement in 2018
Bioinformatics, Inc. is a market research firm supporting the analytical instrumentation and life science industries.Their expertise includes assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customers’ brand loyalty, and evaluating brand strength and positioning. Their multi-disciplinary team is comprised of industry veterans, market research experts, consultants and survey statisticians.

PBS Biotech

Venture Round in 2023
PBS Biotech, Inc, produces the easiest to use and most technologically-advanced bioreactors for the pharmaceutical industry. Their single-use bioreactors have the smallest per liter volume footprints and are fully scalable for any stage of the cell culture process, from R&D to clinical to cGMP production. They provide efficient, cost-effective disposable systems and top-notch technical services to help their customers solve complex cell culture challenges.

SGI-DNA, Inc.

Private Placement in 2019
SGI-DNA, Inc. provides genomic tools to advance scientific discovery. Its products include BioXpTM 3200 systems and Gibson assembly reagents. SGI-DNA, Inc. was formerly known as Synthetic Genomics Solutions, lnc. The company was founded in 2011 and is based in San Diego, California. SGI-DNA, Inc. operates as a subsidiary of Synthetic Genomics, Inc.